Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health care if RBC…
The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After all, a…
The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation found itself in.
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol drug patent.
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the S&P for the first time since early in 2011, despite displaying higher…
